Biotech Values

[DewDiligence]

Example of protesting too much, from ABT’s 4Q10 CC:

http://seekingalpha.com/article/248886-abbott-laboratories-ceo-discusses-q4-2010-results-earnings-call-transcript?part=qanda

Jami Rubin (Goldman Sachs): …you didn't talk about the potential to spin-off or sell some of these businesses for which you are not getting any credit for… I mean, that is one strategy that you might want to consider if you think the Street isn't appreciating your non-pharma assets. And I'm wondering if you could just comment on that.

Miles White (CEO): I don't make the strategic decisions for the company based on transactions the Street might like to see.

Miles, you just did.